Abstract
RA Marsh, JW Leiding, BR Logan. J Clin Immunol . 2019;39(7):653–667 To evaluate the long-term effect of allogenic hematopoietic stem cell transplant (HCT) on chronic granulomatous disease (CGD)–associated inflammatory bowel disease (IBD) and assess the impact of IBD on transplant outcomes. A total of 145 patients with CGD who underwent allogenic HCT at 26 unique Primary Immune Deficiency Treatment Consortium (PIDTC) centers were included in this study. This was a retrospective study to evaluate clinical characteristics, laboratory findings, treatment and outcomes of patients with CGD who underwent allogenic HCT. CGD status was confirmed by …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
